Trombly Amy Moss 4

What Happened

• Amy Moss Trombly, CEO of Sonoma Pharmaceuticals (SNOA), received a grant of 10,000 restricted stock units (RSUs) on July 9, 2026. The RSUs are recorded at $0.00 per unit (derivative award), with no cash exchanged. This is a compensation award rather than an open-market purchase.

Key Details

• Transaction date and terms: July 9, 2026 — 10,000 RSUs granted at $0.00 per unit (derivative grant).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Vesting and conversion: Each RSU represents a contingent right to one share; RSUs vest on the third anniversary of the grant date or upon a change of control (footnotes F1–F2).
• Purpose: RSUs were awarded for services performed (footnote F3).
• Timeliness: Filing dated July 9, 2026; no late-filing indication in the provided information.

Context

• RSUs are a form of equity compensation and do not represent immediate share ownership — they convert to common stock only if and when they vest. Such grants are common for executives as part of pay and retention programs and do not by themselves signal a buy or sell decision in the open market.